Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection
What this study shows
Phase 2 trial (NCT05835999, EVERLAST) testing this Atlas's open dosing hypothesis directly: whether daily low-dose (0.5 mg/day) or weekly (5 mg/week) everolimus for 24 weeks can improve physiological and molecular hallmarks of aging in insulin-resistant or prediabetic adults aged 55-80, without the metabolic penalty seen with continuous higher-dose rapalog use. Double-blind and placebo-controlled with four arms (everolimus daily, everolimus weekly, and a matching placebo for each), n=106, plus a separate untreated 18-35 cohort for comparison. Primary endpoint is peripheral insulin sensitivity by dual-tracer OGTT; mTORC1 and mTORC2 signalling are secondary endpoints in muscle and blood cells. STATUS: the registry records the trial as COMPLETED, with primary completion 2026-06-30 and completion 2026-07-22. No results are posted yet, so there is nothing to read into the outcome either way.
At a glance
| Evidence type | RT Registered trial, no results yet This is a registered clinical trial with no results reported yet. There is no evidence code until results are published -- registration alone is not evidence of an effect. |
| Study type | Registered Trial |
| Model system | Humans, RCT (registered, completed; no results posted) |
| Journal | ClinicalTrials.gov (registration) |
| Year | — |
| Peer reviewed | No |
| Record last updated | 2026-10-01 |
| Source | ClinicalTrials.gov NCT05835999 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Everolimus – daily 0.5 mg vs weekly 5 mg, 24 weeks |
| Target | mTORC1 |
| Model | Human – RCT (registered, completed, no results posted; age 55–80, insulin-resistant/prediabetic) |
| Effect | No results posted yet (registry status COMPLETED; primary completion 2026-06-30) – tests whether dosing improves aging hallmarks without metabolic penalty |
In the Atlas
Related topics
Open questions that cite this study
- Cited as supporting evidence for the open question Does mTORC1-selective dosing extend lifespan, and is rapamycin's glucose intolerance a cost at all?.
- Cited as supporting evidence for the open question A sensor/autophagy biomarker panel as a surrogate endpoint for human trials.
More studies on this topic
- Midlife Growth Hormone Receptor Ablation Extends Healthy Lifespan and Induces Sex-Specific Hepatic Transcriptional Changes at Single-Cell Resolution (2026)
- The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging (2016)
- Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity (2012)
- Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance. (2026)
Thank you. Your answer was counted anonymously.